AstraZeneca PLC on Tuesday said results from a trial showed promising clinical activity in patients with non-small cell lung cancer.
The Cambridge, England-based pharmaceutical firm said results from the Tropion-Lung02 Phase Ib trial showed datopotamab deruxtecan, combined with pembrolizumab with or without platinum chemotherapy, proved a tolerable safety profile and encouraging clinical activity in patients with non-small cell lung cancer.
These results were presented on Tuesday at the International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.
Datopotamab deruxtecan is a specifically designed TROP2-directed DXd antibody drug conjugate being jointly developed by AstraZeneca and Japanese partner Daiichi Sankyo Co Ltd. TROP2, meaning trophoblast cell-surface antigen 2, is a transmembrane glycoprotein, widely expressed in several types of solid tumours, including NSCLC.
AstraZeneca Chief Medical Officer & Oncology Chief Development Officer Christian Massacesi said: ‘Building on preliminary findings of datopotamab deruxtecan combination therapy in triple-negative breast cancer shared earlier this year, these initial results from Tropian-Lung02 reflect the broader promise of combining existing treatments with antibody drug conjugates.’
Lung cancer is the second most common cancer. NSCLC is diagnosed at an advanced stage in almost 50% of patients and often has a poor prognosis with worsening outcomes after each line of subsequent therapy.
AstraZeneca shares were up 0.4% at 10,754.00 pence on Tuesday afternoon in London. Daiichi Sankyo shares closed down 1.2% at JP¥3,601.00 in Tokyo.
Copyright 2022 Alliance News Limited. All Rights Reserved.
